Skip to main content
Solid Tumor Thoracic Cancer

Thoracic Cancer

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Editor's Choice

Early menopause increases lung disease risk

Menopause before the age of 45 years increases the risk for lung morbidities and mortality in women, regardless of smoking status and whether menopause is natural or medical.

A novel side effect of ICI treatment

The first report of thoracic lymphangitis as an immune-related adverse event in a patient receiving adjuvant ICI treatment for lung cancer.

Unprovoked VTE revealing lung cancer

Open Access Venous Thrombosis Case Study

A case emphasizing the importance of occult cancer screening in patients with unprovoked venous thromboembolism, especially those with risk factors.

Preoperative immunotherapy promising in mesothelioma

Open Access Pleural Mesothelioma Case Study

A patient with advanced pleural mesothelioma experienced dramatic tumor shrinkage after neoadjuvant checkpoint inhibitor therapy, and was able to successfully undergo surgery.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Lung Cancer Clinical Trial Summary

At a glance: The KEYNOTE lung cancer trials

A quick guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in non-small-cell and small-cell lung cancer.

Developed by: Springer Medicine
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare

Case Studies

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

A novel side effect of ICI treatment

The first report of thoracic lymphangitis as an immune-related adverse event in a patient receiving adjuvant ICI treatment for lung cancer.

Unprovoked VTE revealing lung cancer

Open Access Venous Thrombosis Case Study

A case emphasizing the importance of occult cancer screening in patients with unprovoked venous thromboembolism, especially those with risk factors.

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine

Current Reviews

The pros and cons of lung cancer screening

Open Access Lung Cancer Invited Review

Lung cancer (LC) is the leading cause of cancer-related death worldwide [ 1 ]. The premise of lung cancer screening (LCS) is that early detection of LC reduces mortality. Indeed, low-dose computed tomography (LDCT)-based LCS showed a 20–39% …

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future

NSCLC Review Article

While activating RET fusions are identified in various cancers, lung cancer represents the most common RET fusion-positive tumor. The clinical drug development of RET inhibitors in RET fusion-positive lung cancers naturally began after RET fusions …

Targeting DNA Damage Response Deficiency in Thoracic Cancers

SCLC Leading Article

Thoracic cancers comprise non-small cell lung cancers (NSCLCs), small cell lung cancers (SCLCs) and malignant pleural mesotheliomas (MPM). Collectively, they account for the highest rate of death from malignancy worldwide. Genomic instability is a …

Deep learning in pulmonary nodule detection and segmentation: a systematic review

Open Access Pulmonary Nodule Review

Lung cancer is responsible for 18.4% of all cancer deaths globally and is the leading cause of cancer-related mortality worldwide [ 1 ]. Pulmonary nodules, often an early indicator of lung cancer, do not always indicate malignancy [ 2 ]. Early …

NSCLC Podcast

Episode 7: A deep dive into ADAURA

The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC. 

We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.

Dr. Luis Paz-Ares

CME & eLearning

Webinar (Link opens in a new window)

1.25 AMA PRA Category 1 Credit(s)

A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.

Supported by:
  • Roche and Illumina
Developed by: Springer Healthcare IME

eLearning | Interviews | Digital Treatment Map (Link opens in a new window)

1.0 AMA PRA Category 1 Credit(s)

Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.

Supported by:
  • Bayer HealthCare Pharmaceuticals Inc.
Developed by: Springer Healthcare IME

Digital Treatment Map (Link opens in a new window)

Practical, expert-led digital map designed to guide treatment of ALK- and ROS1-mutation positive NSCLC.

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME

Further Reading

The pros and cons of lung cancer screening

Open Access Lung Cancer Invited Review

Lung cancer (LC) is the leading cause of cancer-related death worldwide [ 1 ]. The premise of lung cancer screening (LCS) is that early detection of LC reduces mortality. Indeed, low-dose computed tomography (LDCT)-based LCS showed a 20–39% …

Detection of pulmonary nodules in chest radiographs: novel cost function for effective network training with purely synthesized datasets

Open Access Lung Cancer Original Article

Lung cancer, one of the most common malignant tumors worldwide, caused 1.79 million deaths in 2020 [ 1 ]. Computed tomography (CT) is the gold standard among imaging examinations for diagnosing lung cancer. However, due to its costs and radiation …

A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients

Open Access SCLC Original Research

Lung cancer is a highly prevalent malignant disease and the most common cause of cancer-related deaths worldwide; in Japan, approximately 75,585 deaths (53,247 men and 22,338 women) in 2020 were due to lung cancer [ 1 ]. Approximately 10–15% of all …

Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study

Open Access NSCLC Original Research

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide [ 1 , 2 ]. Although molecular targeted therapies for patients with driver mutations are available, improving prognoses in many regions, many patients …

Related topics

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Read more